Literature DB >> 7034513

Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm.

R Ginsburg, I H Lamb, J S Schroeder, M Hu, D C Harrison.   

Abstract

Twelve patients were entered prospectively into a randomized double-blind study comparing the efficacy of nifedipine and isosorbide dinitrate (ISDN) in the treatment of variant angina pectoris due to coronary artery spasm. Using the diary technique, both anginal episodes and nitroglycerin tablets consumed were recorded during the pretrial, no drug period, and both active drug phases. During the baseline pretrial period, an average of 1.1 anginal episodes/day occurred with reduction to 0.28/day during nifedipine treatment and 0.39/day during ISDN treatment. Headache was the major side effect during ISDN treatment, occurring in 9 of 11 (81%) patients; and nonheart failure related pedal edema during nifedipine treatment, occurring in 4 of 12 (33%) patients. Intolerable side effects necessitating cessation of treatment occurred in two patients during nifedipine treatment and in three patients during ISDN treatment. Patients preferred nifedipine over ISDN because of increased efficacy and fewer uncomfortable side effects. We conclude that both nifedipine and ISDN are effective therapy for coronary spasm, but that nifedipine was more effective and was preferred by the majority of patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7034513     DOI: 10.1016/0002-8703(82)90527-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  Coronary Artery Spasm.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

2.  An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

Authors:  T Edeki; A Johnston; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 4.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 5.  Clinical roles of calcium channel blockers in ischemic heart diseases.

Authors:  Daisuke Sueta; Noriaki Tabata; Seiji Hokimoto
Journal:  Hypertens Res       Date:  2017-01-26       Impact factor: 3.872

6.  Failure of intravascular ultrasound to identify the site of recurrent focal coronary spasm during stenting.

Authors:  T Azeem; D Adlam; A Gershlick
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

Review 7.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 8.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 9.  Coronary artery spasm: Current knowledge and residual uncertainties.

Authors:  Massimo Slavich; Riyaz Suleman Patel
Journal:  Int J Cardiol Heart Vasc       Date:  2016-01-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.